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ABSTRACT
Soft tissue sarcomas are rare mesenchymal tumours accounting for 1% of 
adult malignancies and are fatal in approximately one third of patients. Two of 
the most aggressive and lethal forms of soft tissue sarcomas are angiosarcomas 
and undifferentiated pleomorphic sarcomas (UPS). To examine sarcoma-relevant 
molecular pathways, we employed a lentiviral gene regulatory system to attempt 
to generate in vivo models that reflect common molecular alterations of human 
angiosarcoma and UPS. Mice were intraveneously injected with MuLE lentiviruses 
expressing combinations of shRNA against Cdkn2a, Trp53, Tsc2 and Pten with or 
without expression of HrasG12V, PIK3CAH1047R or Myc. The systemic injection of an 
ecotropic lentivirus expressing oncogenic HrasG12V together with the knockdown of 
Cdkn2a or Trp53 was sufficient to initiate angiosarcoma and/or UPS development, 
providing a flexible system to generate autochthonous mouse models of these 
diseases. Unexpectedly, different mouse strains developed different types of 
sarcoma in response to identical genetic drivers, implicating genetic background as 
a contributor to the genesis and spectrum of sarcomas.
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INTRODUCTION
Soft tissue sarcomas are rare mesenchymal 
malignancies that account for approximately 1% of all 
cancers. The WHO has defined over 100 different soft tissue 
sarcoma subtypes named after the tissue that they most 
closely resemble [1]. Based on molecular characteristics, 
soft tissue sarcomas can be divided in two broad categories: 
sarcomas with simple karyotypes, such as chromosomal 
translocations, and sarcomas with more complex genetic 
profiles, including TP53 mutation, CDKN2A deletion and 
MDM2 amplification [2–4]. 
Undifferentiated pleomorphic sarcomas (UPS), 
previously referred to as malignant fibrous histiocytomas 
(MFH), account for approximately 5% of adult soft tissue 
sarcomas and represent one of the most common types of 
high-grade soft tissue sarcoma. Standard treatment options 
are surgical resection, radiotherapy, and chemotherapy, which 
in many cases are not curative, highlighting the necessity to 
develop novel targeted treatments. It is not clear whether 
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UPS represents a group of de-differentiated sarcomas that 
share a common morphology but which originated from 
different cell types or if all UPS tumours arise from an as-
yet-unidentified common cell of origin [5]. The genetic 
alterations responsible for the development of UPS are 
also incompletely understood. TP53 alterations have been 
identified in 17% of human UPS [2] and CDKN2A loss 
seems to be an alternative to TP53 deletion [3]. HRAS and 
KRAS mutations have been identified in up to 50% of human 
UPS tumours [6–8]. Mouse studies have confirmed that 
the cooperation of oncogenic Kras and Trp53 or Cdkn2a 
deficiency resulted in the development of undifferentiated 
pleomorphic sarcomas in different tissues [9–12]. 
Another clinically aggressive subtype of high-
grade soft tissue sarcoma is angiosarcoma. These 
tumours represent rare malignancies of endothelial 
differentiation that account for approximately 1% of all 
soft tissue sarcomas. Angiosarcomas show a wide anatomic 
distribution and arise spontaneously or secondarily to 
radiation, toxic chemicals (e.g. vinyl chloride) or chronic 
lymphoedema (Stewart-Treves syndrome). Treatment 
options are limited and the prognosis is poor [13]. 
Genetic mutations and amplifications of VEGF, MDM2, 
TP53, CDKN2A, KRAS and MYC have been described in 
angiosarcoma patients [14–17]. MYC gene amplifications 
are commonly found in radiation-induced angiosarcomas 
[18]. A recent publication reported that the majority of 
genetic alterations were found in the p53 and MAPK 
pathways. TP53 was mutated in 35% of the lesions and 
CDKN2A lost in 26%. 53% of angiosarcomas displayed 
MAPK pathway activation, and harboured genetic 
activating mutations in KRAS, HRAS, NRAS, BRAF, 
MAPK1 or inactivating mutations in NF1 and PTPRB1 
[19, 20]. Several in vivo mouse studies showed the 
involvement of loss of function of the p53 tumour 
suppressor in angiosarcoma development [21–23]. In 
addition, the in vivo deletion of Cdkn2a in mice lead to 
the development of lesions which recapitulate human 
angiosarcoma, however, only 30% of the mice displayed 
angiosarcomas within 100 days [24]. Furthermore, 
alterations in the PI3K/AKT/mTOR pathway have 
been identified in a small percentage of patients [19, 
25, 26] and deletion of Tsc1, a tumour suppressor that 
negatively regulates the pathway, induced the formation of 
hemangiosarcomas in mice [27]. Another report showed that 
the in vivo deletion of Notch1 resulted in the development 
of hepatic angiosarcomas with a penetrance of 86% at 50 
weeks after gene deletion [28], although genetic alterations 
in the Notch pathway have not been reported in human 
angiosarcomas. Although these studies have been helpful 
in uncovering aspects of sarcomagenesis, there is limited 
understanding of the interactions between cooperating 
genetic alterations.
In this study we employed a mouse genetic approach 
using the MuLE lentiviral gene regulatory system [10] to 
functionally test the contributions of different candidate 
driver oncogenes and tumour suppressor genes to the 
formation of angiosarcoma and UPS. Different mouse 
strains were injected intraveneously with ecotropic MuLE 
lentiviruses expressing combinations of shRNA against 
Cdkn2a, Trp53, Tsc2 and Pten with or without expression 
of HrasG12V, PIK3CAH1047R or Myc. Tumour development 
was monitored by in vivo imaging. We successfully 
generated new models of angiosarcoma and of UPS based 
on oncogenic HrasG12V expression in combination with 
knockdown of Cdkn2a or Trp53. Unexpectedly, different 
mouse strains developed different types of sarcoma in 
response to identical genetic drivers.
RESULTS
Expression of oncogenic HrasG12V plus 
knockdown of Cdkn2a causes angiosarcoma 
development in SCID/beige mice
To functionally test the contributions of different 
candidate driver oncogenes and tumour suppressor genes 
to the formation of angiosarcoma, we generated a panel 
of lentiviral vectors based on the MuLE system [10] 
(Supplementary Figure 1A), to induce genetic alterations 
that reflect some of the most commonly found alterations 
of human angiosarcomas. We first utilised these ecotropic 
MuLE lentiviruses expressing combinations of shRNA or 
shRNA-miR30 against Cdkn2a, Trp53, Tsc2 and Pten with 
or without expression of oncogenic HrasG12V, oncogenic 
PIK3CAH1047R or Myc vectors to attempt to generate 
panels of genetically-engineered angiosarcoma cell lines 
by infecting a disease-relevant cell type, namely primary 
murine endothelial cells from the spleen (pMSECs). 
Western blotting and real time PCR assays of puromycin-
selected cultured cells infected with these vectors verified 
that they effectively induced the desired changes in gene 
expression (Supplementary Figure 1B–1E). Consistent 
with an oncogenic activity of these genetic changes, all cell 
lines, with the exception of HrasG12V expression alone and 
HrasG12V expression plus shTrp53, exhibited increased rates 
of proliferation (Supplementary Figure 2A). The absence 
of increased proliferation induced by oncogenic HrasG12V 
or oncogenic HrasG12V plus Trp53 knockdown is likely to 
be mediated by the upregulation of p16INK4A protein 
expression observed in pMSEC cells infected with these 
vectors (Supplementary Figure 1B) as removal of this 
putative proliferative barrier by knockdown of Cdkn2a 
increased cellular proliferation (Supplementary Figure 2A).
To further investigate potential transformed 
cellular behaviour we cultured cells of all genotypes 
on low-attachment plates, however none of the genetic 
combinations allowed the proliferation of cells as spheres 
or masses (data not shown), indicating that they do not 
have anchorage-independent proliferation capacity. We 
next asked whether these cellular systems might represent 
experimentally tractable allograft tumour models by 
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injecting wild type pMSECs or shCdkn2a plus HrasG12V 
pMSECs subcutaneously into SCID/beige immunodeficient 
mice. Within one month of injection, both the wild type and 
shCdkn2a plus HrasG12V cells formed blood-filled lesions 
(Supplementary Figure 2B) that were lined with CD31-
positive endothelial cells with atypical nuclei growing either 
as single layers or in papillary projections (Supplementary 
Figure 2C). The injected cells apparently have the capacity 
to co-opt or integrate into local blood vessels, resulting in 
large blood-filled vascular structures. Based on the fact 
that this phenotype also arose following injection of wild 
type pMSECs in the absence of oncogene activation or 
tumour suppressor inactivation, we conclude that this ex 
vivo engineered cellular system does not represent a good 
allograft model system for angiosarcoma.
We next sought to assess the tumour forming 
capacity of the same genetic changes that were tested in 
the experiments above directly in vivo. 4–6-week-old 
SCID/beige mice were intravenously injected via the tail 
vein with concentrated ecotropic MuLE vectors that carried 
an expression element for firefly luciferase (Figure 1A) 
in order to label infected cells and to trace potential 
tumour development in vivo over time. The intravenous 
injection of an ecotropic lentivirus expressing oncogenic 
HrasG12V together with knockdown of Cdkn2a (n = 21 of 
32 injected mice) or Trp53 (n = 2 of 4 injected mice) in 
SCID/beige mice induced increases in luciferase signals 
over 4–8 weeks (Figure 1B and Supplementary Figure 3A). 
These signals were widely distributed in different organs 
throughout the body. One of three mice injected with a 
vector expressing only oncogenic HrasG12V developed 
signals in the brain approximately 6 months after injection. 
None of the other viruses was sufficient to cause any large 
increases in luciferase signal within 6 months of injection, 
demonstrating that these combinations of genetic alterations 
are not oncogenic in this setting.
Dissections of mice revealed that the increased 
luciferase signals corresponded to the presence of bloody-
appearing tumours in different organs (Figure 1C and 1D 
and Supplementary Figure 3). From 32 mice injected with 
shCdkn2a plus HrasG12V MuLE vectors, 21 mice developed 
a total of 24 tumours in various tissues including testicle 
(n = 9, 38%), brain (n = 7, 30%), spleen (n = 2, 8%), uterus 
(n = 2, 8%), ovary (n = 1, 4%), lung (n = 1, 4%), colon 
(n = 1, 4%) and eye (n = 1, 4%). Histological analysis 
of these tumours revealed poorly demarcated malignant 
neoplasms with hemorrhage and irregular, anastomosing 
vascular channels. Endothelial lining showed 
multilayering and intraluminal tufting with nuclear 
atypia, hyperchromasia, enlargement and irregularity 
(Supplementary Figure 3A, arrowheads). Mitotic activity 
was variable and back-to-back vascular channels appeared 
sieve-like. Atypical cells were either spindled, epitheloid 
or mixed. There was more solid growth in more poorly 
differentiated areas. Intraluminal erythrocytes were a 
common feature as well as large areas filled with red blood 
cells. Tumour cells exhibited high levels of expression 
of H-RAS in comparison to surrounding normal tissue, 
indicating that the MuLE virus is functional in vivo 
(Supplementary Figure 3B). Positive immunoreactivity 
to antibodies against the endothelial cell marker proteins 
CD31 and von Willebrand Factor (vWF) confirmed the 
endothelial differentiation of the tumour cells (Figure 2A). 
The lesions showed variable staining for VIMENTIN, 
DESMIN and SMOOTH MUSCLE ACTIN (SMA), 
ranging from an absence of staining to some tumours 
showing strong positivity (Figure 2A). None of the tumours 
exhibited nuclear staining for the skeletal muscle markers 
MYOD1 and MYOGENIN (Figure 2A). Supplementary 
Figure 4 shows positive and negative control stainings 
for the different antibodies employed throughout this 
study. Tumours that arose in Trp53 knockdown plus 
oncogenic HrasG12V injected mice displayed an identical 
histological appearance and immunohistochemical staining 
profile to tumours in Cdkn2a knockdown plus oncogenic 
HrasG12V injected mice (Figure 2B). In summary, these 
histological and molecular features are consistent with 
a diagnosis of angiosarcoma. Indeed, analyses of three 
human angiosarcomas revealed that they have a simlar 
histological appearance and exhibit a similar pattern of 
immunoreactivity to the mouse tumours (Figure 2C). We 
conclude that we have developed a rapid autochthonous 
mouse model of angiosarcoma that is trackable via live 
animal imaging and that reflects the frequent genetic 
alterations that arise in human angiosarcoma tumours.
Different immunocompetent mouse strains 
display different types of soft tissue sarcomas in 
response to expression of oncogenic HrasG12V plus 
loss of Cdkn2a function 
To more accurately model the complexities of 
tumour development in humans it would be desirable to 
have tumour models that arise in immunocompetent mice. 
We therefore investigated whether similar tumours arose 
in response to intravenous injection of shCdkn2a plus 
HrasG12V MuLE vectors in the Fox Chase CB17, 129/Sv 
and C57BL/6 mouse strains.
Fox Chase CB17 mice carry the immunoglobulin 
heavy chain allele from C57BL/Ka mice on a BALB/c 
background. They serve as an ideal control for SCID/beige 
mice as they represent the identical genetic background 
but have a normal immune system. Within 4 weeks, 7 of 
8 (88%) Fox Chase CB17 mice injected intraveneously 
with shCdkn2a plus HrasG12V MuLE vectors developed 
angiosarcomas with comparable growth kinetics and 
histology to those that arose in SCID/beige mice 
(Supplementary Figure 5A). The anatomic distribution of 
the tumours in Fox Chase CB17 mice was similar to the 
tumour distribution seen in SCID/beige mice and included 
brain (n = 4, 50%), testicle (n = 3, 38%) and spleen (n = 1, 
12%) (Supplementary Figure 5B). The tumours presented 
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as bloody lesions and stained positively for CD31 and 
vWF by immunohistochemistry. Like the tumours in 
SCID/beige mice, these tumours also showed variable 
staining for VIMENTIN, DESMIN and SMA as well as 
an absence of staining for MYOD1 and MYOGENIN 
(Supplementary Figure 5C). These experiments 
demonstrate that a competent immune system does not 
affect tumour formation and provide a new autochthonous 
angiosarcoma model in an immunocompetent background. 
To investigate sarcoma formation in mouse 
backgrounds that are more commonly utilised for 
biomedical research we next employed 129/Sv mice. 
Intraveneous injections of shCdkn2a plus HrasG12V MuLE 
viruses in 129/Sv mice (n = 8) caused a strong luciferase 
signal increase and the development of multiple tumours 
Figure 1: HrasG12V expression plus knockdown of Cdkn2a or Trp53 causes angiosarcomas in SCID/beige mice. 
(A) Schematic of MuLE vectors simultaneously expressing combinations of shRNAs against Cdkn2a, Trp53, Pten and Tsc2 with or without 
expression of HrasG12V, Myc or PIK3CAH1047R and a Luciferase reporter. (B) Bioluminescence imaging 4, 11, 20, 28 and 36 days after the 
injection of MuLE lentiviruses expressing shRNA against Cdkn2a together with HrasG12V into the tail veins of 4-6-week-old SCID/beige 
mice. Numbers of mice that developed tumours and total number of injected mice are shown for each construct. (C) Bioluminescence 
imaging and (D) photographs showing examples of tumour-bearing organs from shCdkn2a plus HrasG12V and shTrp53 plus HrasG12V 
injected animals. Scale bar: 10 mm. 
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with 100% penetrance within 4 weeks (Figure 3A and 3B, 
Supplementary Figure 6A). Bloody-appearing tumours 
were observed in testicles of 75% of male mice (n = 3) 
and in uteri (n = 2) and ovaries (n = 2) of 50% of female 
mice. 25% of mice carried lesions in the spleen (n = 2), 
and 13% in lung (n = 1) and brain (n = 1), similar to 
results in SCID/beige mice. However, all female mice 
(n = 4) additionally developed subcutaneous tumours (n = 5) 
that were located in the head and neck region and close to 
the subcutis of the vulva. These tumours were solid and 
white in appearance (Figure 3C, last column). Neither 
the sub-cutaneous location, nor the gross morphological 
appearance, were ever seen in tumours in SCID/beige or 
Fox Chase CB17 mice. While all of the bloody-appearing 
Figure 2: Histological and molecular characterisation of angiosarcomas. H&E and immunohistochemical stainings using the 
indicated antibodies of tumours derived from the systemic injection of (A) shCdkn2a plus HrasG12V and (B) shTrp53 plus HrasG12V viruses. 
(C) Stainings of a human angiosarcoma tumour. Similar staining patterns were observed in two additional cases from different patients. 
Low magnification scale bars: 1000 µm and high magnification scale bars: 100 µm. 
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Figure 3: HrasG12V expression plus knockdown of Cdkn2a causes angiosarcomas and undifferentiated pleomorphic 
sarcomas in 129Sv mice. (A) Bioluminescence imaging 5, 13, 20, 26 and 33 days after the injection of MuLE lentiviruses expressing 
shRNA against Cdkn2a together with HrasG12V into the tail veins of 4-6-week-old 129/Sv mice. (B) Bioluminescence imaging showing 
examples of tumour-bearing organs.. (C) H&E and immunohistochemical stainings using the indicated antibodies. Low magnification scale 
bars: 1000 µm and high magnification scale bars: 100 µm.
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tumours exhibited an identical histological appearance 
and pattern of immunoreactivity similar to tumours that 
arose in SCID/beige mice (Figure 3C, Supplementary 
Figure 6B), classifying them as angiosarcomas, the 
subcutaneous tumours exhibited a completely different 
histology and immunohistochemical staining profile. 
These tumours contained cells with rhabdoid features; 
i.e., large polygonal cells with gigantic bizarre nuclei 
(Figure 4A; arrowheads), abundant, deeply eosinophilic 
cytoplasm in a tadpole- or racquet shape and growing 
in a storiform pattern. Nuclei displayed high mitotic 
indices, irregular nuclear membranes, and eosinophilic 
cytoplasmic inclusions. These tumors showed necrotic 
regions, acute inflammatory responses and were highly 
invasive, infiltrating surrounding tissues including 
muscle and fat (Figure 4A, arrows). The absence 
of apparent features of any definable cell lineage is 
suggestive of a diagnosis of undifferentiated pleomorphic 
sarcoma (UPS). Indeed, while these tumours showed high 
levels of H-RAS expression in comparison to adjacent 
normal tissue (Figure 4C, 4D) and were immunoreactive 
for the common mesenchymal marker VIMENTIN, the 
tumour cells did not stain for lineage markers including 
CD31, vWF, DESMIN, SMA, MYOD1 or MYOGENIN 
(Figure 3C, last column). Given the subcutaneous 
location of these tumours, we further investigated 
whether the tumours might potentially represent 
sarcomatoid variants of malignancies derived from a 
skin cell. Tumours in 129/Sv mice stained negatively 
for the melanoma marker protein PMEL (the HMB45 
antigen) (Figure 4E). Melanomas, as well as other types 
of neural lineage-derived tumours are typically diffusely 
positive for S100 and PMEL. The majority of tumour 
cells in tumours in 129/Sv mice were negative for S100 
but some scattered cells within the tumour displayed 
positive immunoreactivity for S100 (Figure 4F). Since 
macrophages also stain positively for S100, it is likely 
that this staining is due to the presence of inflammatory 
cells. Tumour cells in human sarcomatoid squamous cell 
carcinomas typically exhibit nuclear immunoreactivity 
for p63 [29]. While normal skin showed strong nuclear 
p63 immunoreactivity as an internal positive control, 
only a small number of scattered cells in tumours in 
129/Sv mice displayed weak cytoplasmic staining 
for p63 (Figure 4G), arguing against a diagnosis of 
sarcomatoid squamous cell carcinoma. Tumours were 
also completely negative for the epithelial marker 
EpCAM (Figure 4H), but scattered cells within the 129/
Sv subcutaneous tumours (Figure 4I), as well as rare 
cells in angiosarcomas in SCID/beige mice (Figure 4J), 
reacted with a pan-CYTOKERATIN antibody, another 
epithelial marker. However, since human sarcomas, 
including UPS and angiosarcoma, can contain cells that 
are immunoreactive for pan-CYTOKERATIN caution 
should be taken in interpreting this staining as providing 
strong evidence of epithelial origin [30]. Positive 
control stainings of all of these antibodies are shown in 
Supplementary Figure 4.
Given the absence of morphologic features of 
any cellular lineage, the absence of clear evidence for 
positivity of tumour cells for a panel of lineage markers 
and absence of strong and diffuse pan-CYTOKERATIN 
staining we therefore favour the diagnosis of these 
tumours as high-grade UPS Not Otherwise Specified in 
keeping with WHO diagnostic guidelines. However, since 
the differential diagnosis of UPS versus sarcomatoid 
carcinoma is necessarily a diagnosis of exclusion, it 
remains formally possible that these tumours might 
represent an unknown type of undifferentiated sarcomatoid 
carcinoma arising from a cell type that we have not been 
able to identify. As already known from human tumour 
specimens, the differential diagnosis of these lesions 
remains a continuous matter of debate. Importantly, these 
analyses show that 129/Sv mice develop two different 
types of tumours, angiosarcomas and UPS, in response to 
the same oncogenic stimulus. 
To further investigate the effect of genetic 
background on tumour formation, we injected C57BL/6 
mice with shCdkn2a plus HrasG12V MuLE lentiviruses. 
Within 4–8 weeks of injection both male and female 
C57BL/6 mice showed large increases in luciferase signal 
and developed subcutaneous lesions with 92% penetrance 
(12 of 13 injected mice) (Figure 5A and 5B). Tumours 
(n = 12) that developed in C57BL/6 mice were solid 
and white in appearance like those seen in female 129/
Sv mice. They were subcutaneous and located either in 
the head and neck area, lower leg or at the junction of 
the tail and spine. These tumours exhbited an identical 
histological appearance to the UPS tumours that arose 
in 129/Sv mice (Figure 4B). These tumours similarly 
showed an absence of staining for all of the markers that 
were used to characterise the tumours in 129Sv mice, 
except VIMENTIN (Figure 5C). Based on these results 
we conclude that shCdkn2a plus HrasG12V MuLE viruses 
solely cause high-grade UPS in C57BL/6 mice. 
DISCUSSION
Major hurdles in studying sarcoma pathologies are 
the relative rarities of the human diseases and the absence 
for many sarcoma subtypes of good pre-clinical models. 
Here, we used the MuLE lentiviral gene regulatory system 
[10] to investigate the molecular genetics underlying the 
pathogenesis of two types of soft tissue sarcomas, namely 
angiosarcoma and UPS. The MuLE system allows the 
direct introduction of multiple genetic alterations in 
somatic cells in vivo by lentiviral injection. Bypassing 
germline transgenic approaches has benefits in terms of 
time and costs and offers flexibility in terms of the strains 
of mice that can be used for the experiments, allowing 
comparisons between different genetic backgrounds. 
Guided by the genetics of human angiosarcomas and UPS 
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Figure 4: High grade, locally invasive undifferentiated pleomorphic sarcomas form in 129/Sv and C57BL/6 mice. 
(A, B) High magnification images of H&E stained tumour sections derived from the intraveneous injection of shCdkn2a plus H-RasG12V 
viruses in (A) 129/Sv mice and (B) C57BL/6 mice. Arrowheads indicate atypical nuclei and arrows indicate entrapped muscle fibres. 
Images depict tumour invasion into the surrounding muscle or fat tissue. (C, D) Immunohistochemical staining using an anti-H-RAS 
antibody showing high H-RAS expression in a subcutaneous tumour (C) but absence of staining in adjacent normal tissue (D). (E–I) 
Representative immunohistochemical staining patterns for the indicated antibodies in subcutaneous tumours. In (G) the margin between 
normal skin (p63 nuclear positive) and the tumour is shown by a dotted line. (J) Occasional cells in angiosarcoma tumours from SCID/
beige mice stain positively for pan-CYTOKERATIN. Scale bars: 100 µm.
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Figure 5: HrasG12V expression plus knockdown of Cdkn2a causes undifferentiated pleomorphic sarcomas in C57BL/6 
mice. (A) Bioluminescence imaging 8, 15, 30 and 36 days after the injection of MuLE lentiviruses expressing shRNA against Cdkn2a 
together with HrasG12V into the tail veins of 4-6-week-old C57Bl/6 mice. (B) Bioluminescence imaging showing examples of a subcutaneous 
tumour prior to (left) and after (right) resection. (C) H&E and immunohistochemical stainings using the indicated antibodies. Scale bars: 
100 µm.
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tumours, we functionally tested the contributions of the 
candidate sarcoma tumour suppressors Cdkn2a, Trp53, 
Tsc2 and Pten and the candidate oncogenes HrasG12V, 
PIK3CAH1047R or Myc. We discovered that the systemic 
injection of ecotropic lentiviruses expressing oncogenic 
HrasG12V together with the knockdown of Cdkn2a or 
Trp53 was sufficient to initiate angiosarcoma formation 
in multiple organs in SCID/beige mice. shCdkn2a plus 
HrasG12V MuLE viruses also induced angiosarcoma 
formation in Fox Chase CB17 and 129/Sv mice, but 
surprisingly additionally caused UPS development in 129/
Sv mice and only UPS development in C57/BL6 mice. 
These observations are consistent with the fact that RAS-
MAPK and p53 pathway alterations are frequently found 
in high-grade soft tissue sarcomas, such as angiosarcomas 
and UPS [2, 3, 6, 7, 19]. 
Our experimental approach provides new models of 
at least some of the genetic subsets of human angiosarcomas 
and UPS tumours. It should also be noted that while 
histological and immunohistochemical analyses revealed 
numerous similarities between mouse and human tumours, 
there are differences in terms of the anatomical sites where 
the mouse model tumours arise and the most frequent sites 
where naturally occurring human counterpart tumours 
arise. Mouse angiosarcomas in our model arose most 
frequently in the brain, genital organs and spleen. Human 
angiosarcomas are most frequently found in the skin (60%), 
deep soft tissue (25%), breast (8%) and more rarely in liver 
and spleen [1]. There are also examples of cases of human 
angiosarcomas arising in the testes [31], uterus and ovaries 
[32], brain [33], lungs [34] and colon [35], which are all 
sites at which tumours were observed in our mouse models. 
Since endothelial cells are present in all tissues in the body, 
it appears that angiosarcomas have the potential to arise in 
any organ in humans. In our mouse model, the anatomical 
distribution of tumours is likely to be influenced by the 
method of intravascular injection, which will presumably 
influence the likelihood of viral infection at different sites 
in the animal. In contrast, UPS tumours in our models 
were always localised subcutaneously. In humans UPS can 
arise anywhere in the body but most frequently occurs in 
lower extremeties and sometimes in the retroperitoneum, 
head and neck and breast. These tumours typically arise in 
deep subfascial tissue, but about 10% of UPS are primarily 
subcutaneous [1], similarly to the tumours that arise in our 
mouse models.
Genetic cooperation between RAS pathway 
activation and loss of Cdkn2a tumour suppressor function 
has been shown in other mouse models of sarcomas. 
Intramuscular injection of Adeno-Cre in the leg of loxP-
STOP-loxP-KrasG12D/+;Cdkn2afl/fl mice caused UPS 
development [9, 11] and we have previously shown 
that intramuscular injection of the same shCdkn2a plus 
HrasG12V or shTrp53 plus HrasG12V MuLE lentiviruses that 
were used in this study caused the developement of high-
grade UPS [10]. It is noteworthy that injection of these 
viruses into skeletal muscle in SCID-beige mice caused 
UPS [10] but intravenous injection caused angiosarcoma, 
whereas in C57/BL6 mice both modes of injection caused 
UPS formation [10]. Our data demonstrate that the same 
combination of genetic drivers can cause different types of 
tumours based not only on the site of viral delivery, likely 
due to infection of different cell types, but also based on 
the genetic background of the mouse strain.
Why does intraveneous, lentiviral-mediated delivery 
of the same genetic alterations cause different tumours in 
different strains of mice? One possibility relates to genetic 
modifiers such as allelic variants, sequence differences, 
epigenetic modifications and gene expression levels that 
could potentially influence tumour phenotypes [36]. There 
is precedent for the fact that identical genetic alterations can 
result in different phenotypes in different mouse strains. 
One example is that the incidence of mammary tumours 
varies among strains heterozygous for Trp53, with C57BL/6 
mice being resistant and BALB/c mice being susceptible 
[37, 38]. Indeed, BALB/c mice carry an allelic variant 
of Cdkn2a that leads to compromised p16 activity, likely 
causing an increased susceptibility to develop certain 
tumours [39, 40]. In the context of the results of the present 
study, it might be possible in future long-term and large-
scale studies to utilise multi-generational interbreeding 
strategies between C57BL/6 and Fox Chase CB17 strains, 
coupled with genomic analyses, to narrow down loci that 
contribute to the type of sarcoma that develops in response 
to oncogenic HrasG12V expression and Cdkn2a knockdown. 
By extension, our observations highlight the fact that also 
in humans the genetic background of every individual may 
potentially influence the outcome of oncogenic mutations 
in terms of what type of sarcoma develops. In this context, 
it is noteworthy that a study of UPS tumours in Korean 
patients identified a high frequency of oncogenic KRAS 
and HRAS mutations [6], but a study by the same authors 
of UPS tumours in American patients revealed that these 
tumours lacked KRAS and HRAS mutations [7], arguing 
that different human genetic backgrounds (or environmental 
factors) may select for different oncogenic mutations during 
the course of sarcoma development. To further investigate 
this issue, we analysed the mutation spectrum of a series of 
48 human UPS tumours from the TCGA provisional dataset 
using cBioPortal software (http://www.cbioportal.org/
study?id=sarc_tcga#summary) (Supplementary Figure 7). 
The ethnicity of this patient cohort is 42 white, 4 black 
or African American, 2 hispanic or latino, 2 unknown but 
no reported Asian patients. Interestingly, this set of UPS 
tumours does not display activating point mutations in 
any of the RAS-family genes in keeping with the previous 
study of American patients [7]. However, the majority of 
these tumours exhibit loss-of-function point mutations or 
copy number deletions of the TP53 and CDKN2A tumour 
suppressor genes and all but one of these tumours exhibit 
multiple copy number gains or amplifications of genes 
involved in the RAS-RAF-MEK-MAPK signalling cascade, 
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as well as copy number losses of the NF1 tumour suppressor 
gene that negatively regulates signalling by this cascade. 
These results give rise to a hypothesis that could be tested 
in future studies, namely that chromosomal copy number 
alterations rather than point mutations account for activation 
of the RAS-signalling pathway in combination with loss 
of the CDKN2A-TP53 tumour suppressor pathways to 
drive UPS tumour formation in non-Asian individuals. In 
summary, we believe that our functional tumour modelling 
studies, combined with the above-described genetic 
analyses, further emphasise the need to consider individual 
tumours at the molecular level rather than at the level of 
histo-pathological appearance when thinking about the 
development and clinical application of new molecularly 
targeted sarcoma therapies. 
A second possible explanation for the different 
tumour types that arise in the different mouse stains relates 
to cellular tropism. It remains possible that MuLE viruses 
might infect different spectra of cells in different mouse 
strains, potentially due to different expression levels of 
the mouse cationic amino acid transporter 1 (mCAT1) 
protein that serves as the virus receptor. However, to 
our knowledge, nothing is known about the expression 
patterns of this protein in different strains of mice and in 
our experience identifying infected cells in vivo is only 
possible using genetic reporter mouse lines [10]. However, 
the identification of infection of a particular cell type is 
at best a hint that it might be able to be transformed and 
act as the cell of origin of a tumour. Consistent with the 
idea that angiosarcoma and UPS tumours might arise due 
to the infection of different cell types it is noteworthy that 
all of the UPS tumours that arose in 129/Sv and C57BL/6 
mice were subcutaneous, whereas angiosargomas in 129/
Sv, Fox Chase CB17 and SCID/beige mice were found in 
several different organs. These differences in anatomical 
distribution are suggestive of different cells of origin 
of these tumours. Proof of cell of orgin of a tumour 
requires a lineage tracing experiment. Given the fact that 
angiosarcomas express markers of endothelial cells and 
are intimately connected to the normal vascular network 
of the mouse (blood-filled lesions) it appears likely that 
the cell of origin of these tumours are vascular endothelial 
cells. Future experiments could involve utilising lineage 
tracing experiments using a Cre-driver such as Tie2-
CreERT2 [41] to genetically label endothelial cells prior to 
injection of  shCdkn2a plus HrasG12V MuLE lentiviruses. 
A potential caveat of these studies may however be that 
the tumour type that will arise will also be dictated by 
the (likely mixed) genetic background of the strain of the 
lineage tracing mouse. The cell of origin of UPS remains 
unknown and it is not clear whether UPS represent a group 
of de-differentiated sarcomas which share a common 
morphology but originated from different cell types or if all 
UPS tumours arise from a common cell of origin [5]. One 
interesting hypothesis that could be experimentally tested 
is that adult mesenchymal stem cells (MSCs) have been 
proposed as the cell of origin of human UPS [42–45]. It 
has been shown that the overexpression of oncogenic Kras 
in cultured MSCs isolated from the bone marrow of Trp53 
knockout C57BL/6 mice caused transformation of these 
cells in vitro [46]. We have shown that ecotropic MuLE 
lentiviruses can infect a variety of cultured primary cells, 
including mouse embryonic stem cells [10] and although 
bone marrow represents the main source of MSCs, MSCs 
also exist in low numbers in peripheral blood [47]. It is 
theoretically possible that infected MSCs in the peripheral 
blood could give rise to UPS in 129/Sv and C57BL/6 mice. 
In summary, these new experimental models will 
facilitate future pre-clinical studies for establishing 
new therapeutic interventions for these aggressive 
malignancies. While it is somewhat surprising that the 
other tested candidate tumour suppressors and oncogenes 
were not sufficient to cause tumour formation, given their 
frequent mutational alteration in human angiosarcomas 
and UPS, the flexible nature of the MuLE system should 
also allow the testing of other candidate oncogenes, 
modifier genes or tumour suppressor genes that will likely 




SCID/beige mutant mice (C.B-17/CrHsd-
PrkdcScidLystbg-J) and C57BL/6JRccHsd mice were obtained 
from Envigo. 129S2/SvPasOrlRj mice were obtained from 
Janvier Labs and Fox Chase CB17™ mice (C.BKa-lghb/
lcrCrl) were obtained from Charles River Laboratories. All 
mouse experiments were approved by the Veterinary Office 
of the Canton of Zurich under the licence 137/2013.
Generation of MuLE vectors 
The majority of the MuLE Entry and Destination 
vectors used in this study were previously described 
[10] and were recombined using MultiSite Gateway LR 
2-fragment recombinations to generate the final viral 
constructs. New MuLE Entry vectors carrying 7SK 
promotor-driven expression of shRNA against Tsc2 (Sigma, 
TRCN0000306244) and CMV promotor-driven expression 
of hemagglutinin (HA) tagged phosphoinositide 3-kinase 
H1047R (HA-PIK3CA H1047R, Addgene 12524, deposited 
by Dr. Jean Zhao) were generated.  Ecotropic lentiviral 
vectors were produced by using calcium phosphate-
mediated transfection of HEK293T cells and the viral 
preparation was concentrated as described previously [10]. 
Culture, infection and assays of pMSECs
C57BL/6 mouse primary spleen endothelial cells 
(pMSECs, C57-6057, Cell Biologics) were cultured according 
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to the instructions of the supplier in complete mouse endothelial 
cell medium (M1168, Cell Biologics) in a humidified 5% 
(v/v) CO2 incubator at 37° C. 50% confluent pMSECs were 
transduced with lentiviral vectors in the presence of 4 μg/ml 
polybrene (Hexadimethrine bromide, 107689, Sigma-Aldrich). 
Puromycin (ANT-PR-1, InvivoGen) was added to cultures 48 
h after infection and drug selection continued until all control 
cells were dead. pMSECs were seeded in triplicates at density 
of 2,000 cells per well in 96-well plates and analysed after 1, 3, 
5 and 7 days using the SRB assay [48]. For allograft assays, 1 
× 106 pMSECs were injected subcutaneously into SCID/beige 
mice.
In vivo tumour formation assays
Concentrated ecotropic lentiviruses were injected 
(3 × 105 infectious viral particles in a volume of 10 ml/kg) 
using a 30G insulin syringe into the lateral tail vein of 
4–6-week old mice. Noninvasive in vivo bioluminescence 
imaging was performed using the IVIS Spectrum (Perkin 
Elmer) together with the Living Image software (version 
4.4). Mice were anaesthetized by using 2.5% isoflurane. 
During imaging, the isoflurane levels were reduced to 
1.5%. All fluorescence measurements were performed in 
epi-fluorescence mode. For bioluminescence imaging, mice 
were injected subcutaneously with 150 mg/kg D-luciferin 
(Caliper, no. 122796) and imaged 15 min after injection.
Immunohistochemistry
Tumour-bearing organs were resected, fixed in 
10% formalin, paraffin-embedded and cut in 5 µm thick 
sections. Immunohistochemical analysis was performed as 
described [49]. The antibodies used in this study were anti-
CD31 (1:200, ab28364, Abcam), anti-DESMIN (1:100, 
D1033, Sigma-Aldrich), anti-EpCAM (1:500, ab71916, 
Abcam), anti-H-RAS (1:100, GTX116041, GeneTex), 
anti-MYOD1 (1:100, M3512, Dako), anti-MYOGENIN 
(1:500, M3559, Dako), anti-pan-CYTOKERATIN (1:100, 
BMA Biomedicals AG, T1302), anti-PMEL(HMB45) 
(1:100, Abcam, ab137078), anti-p63 (1:500, ab124762, 
Abcam), anti-alpha-SMA (1:5000, ab5694, Abcam), 
anti-S100 (1:2000, S100 DAKO A/S), anti-VIMENTIN 
(1:500, D21H3, Cell Signaling) and anti-von Willebrand 
Factor (vWF) (1:1000, F3520, Sigma-Aldrich).
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-
HCl pH 8.0, 150 mM sodium chloride, 1% (v/v) NP-
40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 
5mM sodium fluoride, 1 mM sodium orthovanadate, 1 
mM PMSF, 1:100 Protease Inhibitor Cocktail (Sigma-
Aldrich)) for protein extraction. Proteins were run on 
8–12% acrylamide gels, transferred to nitrocellulose 
membranes and visualized by immunoblotting with the 
following antibodies anti-ß-ACTIN (1:2000, A2228, 
Sigma-Aldrich), anti-H-RAS (1:1000, sc-520, Santa 
Cruz Biotechnology Inc.), anti-MYC (1:1000, AB32072, 
Epitomics (Abcam)), anti-p16 (1:1000, sc-1207, Santa 
Cruz Biotechnology Inc.), anti-p19 (1:1000, sc-32748, 
Santa Cruz Biotechnology Inc.), anti-p53 (1:500, NCL-
p53-CM5p, Novocastra), anti-PTEN (1:1000, sc-7974, 
Santa Cruz Biotechnology Inc.), anti-TSC2 (1:1000, 
3990s, Cell signaling) and anti-VINCULIN (1:5000, 
ab129002, Abcam). 
Real-time PCR
Total RNA was isolated from cells using 
NucleoSpin RNA kit (Macherey-Nagel). cDNA systhesis 
was performed with random hexamer primers and Ready-
To-Go You-Prime First-Strand Beads (GE Healthcare). 
Real-time PCR analysis was performed with SYBR 
Green JumpStart Taq Ready Mix (Sigma-Aldrich) 
and the following primer pairs: S12 (5′-GAAGCTGC 
CAAAGCCTTAGA-3′, 5′-AACTGCAACCAACCACC 
TTC-3′) and PIK3CA (5′- CCACGACCATCATCAGGT 
GAA-3′, 5′- CCTCACGGAGGCATTCTAAAGT-3′).
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